巨型乳腺瘤的长期初级药物治疗:不同卡伯戈林剂量的比较
Hána Václav1, Vaněčková Manuela2, Kršek Michal1
13rd Department of Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Journal of clinical & translational endocrinology
|September 22, 2025
概括
高剂量的卡贝戈林在巨型乳腺瘤患者中加速了益生素正常化,但没有影响瘤缩. 多巴胺激动剂是有效的第一线治疗方法,许多患者最终会停止治疗.
科学领域:
- 内分泌学 在内分泌学.
- 神经外科 神经外科
- 在瘤学瘤学.
背景情况:
- 巨型乳腺瘤 (≥4厘米) 通常用多巴胺激动剂作为第一线治疗来治疗.
- 了解多巴胺激动剂的最佳剂量策略对于有效的治疗结果至关重要.
研究的目的:
- 评估多巴胺激动剂剂量对巨型乳腺瘤患者生化和放射反应的差异效应.
- 评估高剂量卡贝戈林与低剂量卡贝戈林对益生菌素正常化和瘤大小减少的影响.
主要方法:
- 对33名巨型益生菌瘤患者的回顾性分析,这些患者在23年内接受了初级药物治疗.
- 在高剂量 (≥3.5毫克/周) 和低剂量 (1-2.5毫克/周) 卡贝戈林治疗方案之间,对益生菌素正常化和瘤大小减小的比较.
主要成果:
- 较高的卡贝戈林剂量导致更快的益生菌素正常化,但没有加速瘤缩.
- 27%的患者因并发症需要手术,3人因耐药性接受放射治疗.
- 在4/33例患者中,药物治疗可以在10-20年后停止.
结论:
- 多巴胺激动剂对巨型乳腺瘤是安全有效的,在某些情况下可能会停止治疗.
- 较高的卡贝戈林剂量可以提升早期的乳清素正常化,而不会改善最初的瘤缩.
相关概念视频
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Rational Dosage Regimen: Maintenance Dose and Loading Dose
5.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.4K
Insulin: Dosing Regimen and Adverse Effects
689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689
Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
222
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
222
Dosage Regimens: Partial Pharmacokinetic Parameters
155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155


